Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares Outstanding
Ratios

Burning Rock Biotech (BNR) Leases (2019 - 2025)

Burning Rock Biotech has reported Leases over the past 6 years, most recently at $6.0 million for Q4 2025.

  • For Q4 2025, Leases fell 18.55% year-over-year to $6.0 million; the TTM value through Dec 2025 reached $6.0 million, down 18.55%, while the annual FY2025 figure was $6.1 million, 16.06% down from the prior year.
  • Leases for Q4 2025 was $6.0 million at Burning Rock Biotech, up from $4.5 million in the prior quarter.
  • Over five years, Leases peaked at $15.1 million in Q1 2021 and troughed at $1.7 million in Q4 2023.
  • A 5-year average of $8.3 million and a median of $7.1 million in 2022 define the central range for Leases.
  • Biggest five-year swings in Leases: crashed 74.83% in 2023 and later skyrocketed 406.62% in 2024.
  • Year by year, Leases stood at $12.7 million in 2021, then tumbled by 46.51% to $6.8 million in 2022, then crashed by 74.83% to $1.7 million in 2023, then skyrocketed by 334.01% to $7.4 million in 2024, then decreased by 18.55% to $6.0 million in 2025.
  • Business Quant data shows Leases for BNR at $6.0 million in Q4 2025, $4.5 million in Q3 2025, and $5.3 million in Q2 2025.